Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Roivant will sell its potential blockbuster ulcerative colitis drug to Roche for $7.1 billion, less than a year after acquiring it from Pfizer for what …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer

Max Gelman

Senior Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Exclusive: Florida cancer biotech raises $100M Series A

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

Roivant flips ul­cer­a­tive col­i­tis drug to Roche for $7.1B, less than a year af­ter get­ting the drug from Pfiz­er

Senior Editor

Senior Reporter

Sign up to read this article for free.

more like this

Roivant flips ulcerative colitis drug to Roche for $7.1B, less than a year after getting the drug from Pfizer